Secondary analysis of a randomised trial in adults 18–64: recombinant vaccine elicited two-fold higher anti-HA responses to cell-based A and B/Yamagata viruses than standard egg-based vaccine, which raised NA antibodies only to egg-grown antigens.
Secondary analysis
Mishin et al. Hemagglutinin- and neuraminidase-targeting antibody responses after receipt of egg-based inactivated or recombinant influenza vaccines among adults aged 18-64 years